Phase 1/2 Study of Carfilzomib, Pomalidomide, and Dexamethasone (kpd) in Patients (pts) with Relapsed/refractory Multiple Myeloma (RRMM): A Multiple Myeloma Research Consortium Multicenter Study.

Cara Ann Rosenbaum,Leonor Ano Stephens,Vishal Kukreti,Jeffrey A. Zonder,Craig Cole,Todd M. Zimmerman,Donna Ellen Reece,Jesus G. Berdeja,Erica Severson, Andrea Revethis,Brittany Wolfe,Kathryn McDonnell,Jennifer Nam,Kent A. Griffith,Andrzej J. Jakubowiak

Journal of clinical oncology（2016）

Cited 6|Views22

No score

Abstract

8007Background: The combination of carfilzomib (CFZ), pomalidomide (POM) and dexamethasone (DEX) showed very promising activity in advanced RRMM. In this phase 1/2 study, KPd was evaluated in less-...

Translated text

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined